Evidence map›Paper›PMID 32029878›Full record

ArticleScientific reports2020

Genome mining of biosynthetic and chemotherapeutic gene clusters in Streptomyces bacteria.

Kaitlyn C Belknap, Cooper J Park, Brian M Barth, Cheryl P Andam

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 226 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Comparative genome analysis and secondary biosynthetic potential of the Streptomyces microflavus strains isolated from high altitude.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Identification of NovelMicroorganisms · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kaitlyn C Belknap *University of New Hampshire, Department of Molecular, Cellular and Biomedical Sciences, Durham, NH, 03824, USA.
Cooper J Park *University of New Hampshire, Department of Molecular, Cellular and Biomedical Sciences, Durham, NH, 03824, USA.
Brian M BarthUniversity of New Hampshire, Department of Molecular, Cellular and Biomedical Sciences, Durham, NH, 03824, USA.
Cheryl P AndamUniversity of New Hampshire, Department of Molecular, Cellular and Biomedical Sciences, Durham, NH, 03824, USA. Cheryl.Andam@unh.edu.ORCID http://orcid.org/0000-0003-4428-0924
University of New Hampshire · US

Funding

Regulation of Ceramide-Based Therapeutics in Acute Myeloid LeukemiaK22CA190674 · NCI · UNIVERSITY OF NEW HAMPSHIRE · PI BARTH, BRIAN MICHAEL · 2016 to 2018
$485k
National Science Foundation (NSF) 1844430NCI NIH HHS K22 CA190674
6 · The paper itself

Abstract

Streptomyces bacteria are known for their prolific production of secondary metabolites, many of which have been widely used in human medicine, agriculture and animal health. To guide the effective prioritization of specific biosynthetic gene clusters (BGCs) for drug development and targeting the most prolific producer strains, knowledge about phylogenetic relationships of Streptomyces species, genome-wide diversity and distribution patterns of BGCs is critical. We used genomic and phylogenetic methods to elucidate the diversity of major classes of BGCs in 1,110 publicly available Streptomyces genomes. Genome mining of Streptomyces reveals high diversity of BGCs and variable distribution patterns in the Streptomyces phylogeny, even among very closely related strains. The most common BGCs are non-ribosomal peptide synthetases, type 1 polyketide synthases, terpenes, and lantipeptides. We also found that numerous Streptomyces species harbor BGCs known to encode antitumor compounds. We observed that strains that are considered the same species can vary tremendously in the BGCs they carry, suggesting that strain-level genome sequencing can uncover high levels of BGC diversity and potentially useful derivatives of any one compound. These findings suggest that a strain-level strategy for exploring secondary metabolites for clinical use provides an alternative or complementary approach to discovering novel pharmaceutical compounds from microbes.

Indexed as

Multigene FamilyAnimalsAnti-Bacterial AgentsAntineoplastic AgentsBacterial ProteinsBiological ProductsBiosynthetic PathwaysData MiningDrug DevelopmentGenome, BacterialGenomicsPhylogenySecondary MetabolismStreptomycesAnti-Bacterial AgentsAntineoplastic AgentsBacterial ProteinsBiological Products

Identifiers

PMID32029878
PMCPMC7005152
OpenAlexW3005299705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.